Next Article in Journal
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
Next Article in Special Issue
Lung-Targeted Delivery of Cepharanthine by an Erythrocyte-Anchoring Strategy for the Treatment of Acute Lung Injury
Previous Article in Journal
Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
Previous Article in Special Issue
Evaluation of the Cytotoxic, Anti-Inflammatory, and Immunomodulatory Effects of Withaferin A (WA) against Lipopolysaccharide (LPS)-Induced Inflammation in Immune Cells Derived from BALB/c Mice
 
 
Article

Article Versions Notes

Pharmaceutics 2022, 14(8), 1675; https://doi.org/10.3390/pharmaceutics14081675
Action Date Notes Link
article pdf uploaded. 11 August 2022 16:25 CEST Version of Record https://www.mdpi.com/1999-4923/14/8/1675/pdf-vor
article xml file uploaded 12 August 2022 07:24 CEST Original file -
article xml uploaded. 12 August 2022 07:24 CEST Update https://www.mdpi.com/1999-4923/14/8/1675/xml
article pdf uploaded. 12 August 2022 07:24 CEST Updated version of record https://www.mdpi.com/1999-4923/14/8/1675/pdf
article supplementary file uploaded. 12 August 2022 07:24 CEST - https://www.mdpi.com/1999-4923/14/8/1675#supplementary
article html file updated 12 August 2022 07:25 CEST Original file https://www.mdpi.com/1999-4923/14/8/1675/html
Back to TopTop